Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, treatment with two
drugs called nivolumab and ipilimumab have on the participant and salivary cancer.